This is especially important for mutations that have clinical impacts at subclonal frequencies (1) such as the case of TP53 gene mutations (TP53mut) in chronic lymphocytic leukemia (CLL) (7, 8). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.